Literature DB >> 26026161

A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II.

Nathan L Meyers1, Mikael Larsson2, Gunilla Olivecrona3, Donald M Small4.   

Abstract

Apolipoprotein C-II (apoC-II) is the co-factor for lipoprotein lipase (LPL) at the surface of triacylglycerol-rich lipoproteins. LPL hydrolyzes triacylglycerol, which increases local surface pressure as surface area decreases and amphipathic products transiently accumulate at the lipoprotein surface. To understand how apoC-II adapts to these pressure changes, we characterized the behavior of apoC-II at multiple lipid/water interfaces. ApoC-II adsorption to a triacylglycerol/water interface resulted in large increases in surface pressure. ApoC-II was exchangeable at this interface and desorbed on interfacial compressions. These compressions increase surface pressure and mimic the action of LPL. Analysis of gradual compressions showed that apoC-II undergoes a two-step desorption, which indicates that lipid-bound apoC-II can exhibit at least two conformations. We characterized apoC-II at phospholipid/triacylglycerol/water interfaces, which more closely mimic lipoprotein surfaces. ApoC-II had a large exclusion pressure, similar to that of apoC-I and apoC-III. However, apoC-II desorbed at retention pressures higher than those seen with the other apoCs. This suggests that it is unlikely that apoC-I and apoC-III inhibit LPL via displacement of apoC-II from the lipoprotein surface. Upon rapid compressions and re-expansions, re-adsorption of apoC-II increased pressure by lower amounts than its initial adsorption. This indicates that apoC-II removed phospholipid from the interface upon desorption. These results suggest that apoC-II regulates the activity of LPL in a pressure-dependent manner. ApoC-II is provided as a component of triacylglycerol-rich lipoproteins and is the co-factor for LPL as pressure increases. Above its retention pressure, apoC-II desorbs and removes phospholipid. This triggers release of LPL from lipoproteins.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  apolipoprotein; lipase; lipid droplet; lipoprotein metabolism; low-density lipoprotein (LDL); triglyceride

Mesh:

Substances:

Year:  2015        PMID: 26026161      PMCID: PMC4505049          DOI: 10.1074/jbc.M114.629865

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

Review 1.  A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.

Authors:  Anastazia A Kei; Theodosios D Filippatos; Vasilios Tsimihodimos; Moses S Elisaf
Journal:  Metabolism       Date:  2012-02-02       Impact factor: 8.694

Review 2.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

3.  Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.

Authors:  Mikael Larsson; Evelina Vorrsjö; Philippa Talmud; Aivar Lookene; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

4.  Surface pressure-dependent conformation change of apolipoprotein-derived amphipathic α-helices.

Authors:  Matthew A Mitsche; Donald M Small
Journal:  J Lipid Res       Date:  2013-03-25       Impact factor: 5.922

5.  Functional analyses of human apolipoprotein CII by site-directed mutagenesis: identification of residues important for activation of lipoprotein lipase.

Authors:  Yan Shen; Aivar Lookene; Solveig Nilsson; Gunilla Olivecrona
Journal:  J Biol Chem       Date:  2001-11-21       Impact factor: 5.157

6.  Structure of a biologically active fragment of human serum apolipoprotein C-II in the presence of sodium dodecyl sulfate and dodecylphosphocholine.

Authors:  R Storjohann; A Rozek; J T Sparrow; R J Cushley
Journal:  Biochim Biophys Acta       Date:  2000-07-19

7.  Characterization of recombinant wild type and site-directed mutations of apolipoprotein C-III: lipid binding, displacement of ApoE, and inhibition of lipoprotein lipase.

Authors:  H Liu; P J Talmud; L Lins; R Brasseur; G Olivecrona; F Peelman; J Vandekerckhove; M Rosseneu; C Labeur
Journal:  Biochemistry       Date:  2000-08-08       Impact factor: 3.162

8.  Human apolipoprotein C-II forms twisted amyloid ribbons and closed loops.

Authors:  D M Hatters; C E MacPhee; L J Lawrence; W H Sawyer; G J Howlett
Journal:  Biochemistry       Date:  2000-07-18       Impact factor: 3.162

9.  NMR structure of human apolipoprotein C-II in the presence of sodium dodecyl sulfate.

Authors:  C A MacRaild; D M Hatters; G J Howlett; P R Gooley
Journal:  Biochemistry       Date:  2001-05-08       Impact factor: 3.162

10.  Changes in helical content or net charge of apolipoprotein C-I alter its affinity for lipid/water interfaces.

Authors:  Nathan L Meyers; Libo Wang; Olga Gursky; Donald M Small
Journal:  J Lipid Res       Date:  2013-05-13       Impact factor: 5.922

View more
  11 in total

1.  Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.

Authors:  Nathan L Meyers; Mikael Larsson; Evelina Vorrsjö; Gunilla Olivecrona; Donald M Small
Journal:  J Lipid Res       Date:  2017-02-03       Impact factor: 5.922

2.  Development and application of a high throughput one-pot extraction protocol for quantitative LC-MS/MS analysis of phospholipids in serum and lipoprotein fractions in normolipidemic and dyslipidemic subjects.

Authors:  Michael S Gardner; Zsuzsanna Kuklenyik; Antony Lehtikoski; Kayla A Carter; Lisa G McWilliams; Jennifer Kusovschi; Kevin Bierbaum; Jeffrey I Jones; Jon Rees; Gregory Reis; James L Pirkle; John R Barr
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2019-04-22       Impact factor: 3.205

Review 3.  Apolipoproteins in vascular biology and atherosclerotic disease.

Authors:  Anurag Mehta; Michael D Shapiro
Journal:  Nat Rev Cardiol       Date:  2021-10-08       Impact factor: 32.419

Review 4.  Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.

Authors:  Anna Wolska; Richard L Dunbar; Lita A Freeman; Masako Ueda; Marcelo J Amar; Denis O Sviridov; Alan T Remaley
Journal:  Atherosclerosis       Date:  2017-10-20       Impact factor: 5.162

5.  Apolipoprotein C-II Mimetic Peptide Promotes the Plasma Clearance of Triglyceride-Rich Lipid Emulsion and the Incorporation of Fatty Acids into Peripheral Tissues of Mice.

Authors:  Tomohiro Komatsu; Toshihiro Sakurai; Anna Wolska; Marcelo J Amar; Akiko Sakurai; Boris L Vaisman; Denis Sviridov; Stephen Demosky; Milton Pryor; Katsunori Ikewaki; Alan T Remaley
Journal:  J Nutr Metab       Date:  2019-02-03

6.  Association of the lipoprotein lipase and Apolipoprotein C-II gene polymorphisms with risk of dyslipidemia in smokers and non-smokers male.

Authors:  Rithab Ibrahim Al-Samawi; Maha Fadil Smaism
Journal:  Indian Heart J       Date:  2021-12-15

7.  Apolipoprotein E content of VLDL limits LPL-mediated triglyceride hydrolysis.

Authors:  Brynne E Whitacre; Philip Howles; Scott Street; Jamie Morris; Debi Swertfeger; W Sean Davidson
Journal:  J Lipid Res       Date:  2021-12-01       Impact factor: 5.922

Review 8.  Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?

Authors:  Geesje M Dallinga-Thie; Jeffrey Kroon; Jan Borén; M John Chapman
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

9.  Dual binding motifs underpin the hierarchical association of perilipins1-3 with lipid droplets.

Authors:  Dalila Ajjaji; Kalthoum Ben M'barek; Michael L Mimmack; Cheryl England; Haya Herscovitz; Liang Dong; Richard G Kay; Satish Patel; Vladimir Saudek; Donald M Small; David B Savage; Abdou Rachid Thiam
Journal:  Mol Biol Cell       Date:  2019-01-16       Impact factor: 4.138

Review 10.  Apolipoprotein Mimetic Peptides: Potential New Therapies for Cardiovascular Diseases.

Authors:  Anna Wolska; Mart Reimund; Denis O Sviridov; Marcelo J Amar; Alan T Remaley
Journal:  Cells       Date:  2021-03-08       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.